The efficacy of combined treatment with recombinant human tumor necrosis factor-α and 5-fluorouracil is dependent on the development of capillaries in tumor-Reference-Cited by-同舟云学术

The efficacy of combined treatment with recombinant human tumor necrosis factor-α and 5-fluorouracil is dependent on the development of capillaries in tumor

Published:1990-02 Issue:2 Volume:26 Page:93-99
ISSN:0277-5379
Container-title:European Journal of Cancer and Clinical Oncology
language:en
Short-container-title:European Journal of Cancer and Clinical Oncology

Author:

Manda Toshitaka,Nishigaki Fusako,Mukumoto Sueo,Masuda Kikuo,Nakamura Takaaki,Shimomura Kyoichi

Publisher

Elsevier BV

Subject

Oncology

Reference32 articles.

1. An endotoxin-induced serum factor that causes necrosis of tumors;Carswell,1975

2. Human tumor necrosis factor: production, purification and characterization;Aggarwal;J Biol Chem,1985

3. Human tumor necrosis factor: precursor structure, expression and homology to lymphotoxin;Pennica;Nature,1984

4. Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons;Balkwill;Cancer Res,1986

5. Recombinant human tumor necrosis factor—II. Antitumor effect on murine and human tumors transplanted in mice;Sohmura;Int J Immunopharmacol,1986

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dynamic contrast-enhanced MRI using macromolecular contrast media for monitoring the response to isolated limb perfusion in experimental soft-tissue sarcomas;Magnetic Resonance Materials in Physics, Biology and Medicine;2004-10-10

2. Perfusión de extremidad aislada en sarcomas de partes blandas irresecables: un nuevo estándar;Revista Española de Cirugía Ortopédica y Traumatología;2004-01

3. Perfusión de extremidad aislada en Oncología;Revista de Oncología;2003-04

4. Die isolierte Extremitätenperfusion zur Behandlung von Weichteilsarkomen, Transitmetastasen des malignen Melanoms sowie anderen irresektablen Tumoren;Regionale Tumortherapie;2003

5. Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: Credits, debits, and future perspectives;Current Oncology Reports;2001-08